Skip to main content
Premium Trial:

Request an Annual Quote

Inverness Commences Tender Offer for Biosite Shares

NEW YORK (GenomeWeb News) — Inverness Medical Innovations today said it has commenced its tender offer to buy all of Biosite's outstanding shares at a price of $92.50 per share without interest.
Under the cash deal, Inverness would pay an additional $.015205 per share for each day after July 2 that the shares are not accepted for payment.
Inverness, which last week won a bidding war against Beckman Coulter to acquire Biosite, said Biosite's board has approved the sale.
Unless the tender offer is extended, Inverness said, it is set to expire at 12:00 midnight, EST, on June 25.
Inverness said after the deal closes Biosite will operate as a wholly owned Inverness subsidiary.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.